Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 10/20 | 0.37 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MMP14 | P50281 | 3/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178111 | 0.89 | AKR1B1 (0.39) | AKR1B1AKR1A1ALDH1A1MMP14MMP2 | |
| SCHEMBL4260327 | 0.84 | AKR1B1 (0.39) | AKR1B1AKR1A1ALDH1A1 | |
| SCHEMBL4166799 | 0.83 | PLA2G7 (0.48) | AKR1B1AKR1A1RAB9APOLBHSD17B10 | |
| SCHEMBL4254352 | 0.82 | AKR1B1 (0.39) | AKR1B1AKR1A1ALDH1A1MMP14MMP2 | |
| SCHEMBL4163352 | 0.81 | AKR1B1 (0.38) | AKR1B1AKR1A1ALDH1A1MMP14MMP2 | |
| SCHEMBL4167818 | 0.81 | AKR1B1 (0.46) | AKR1B1AKR1A1MMP14MMP2MMP3 | |
| SCHEMBL4167852 | 0.81 | POLB (0.43) | AKR1B1AKR1A1ALDH1A1MMP14MMP2 | |
| SCHEMBL4254379 | 0.80 | AKR1B1 (0.39) | AKR1B1AKR1A1MMP14MMP2MMP3 | |
| SCHEMBL4254387 | 0.80 | CNR1 (0.42) | AKR1B1AKR1A1MMP14MMP2MMP3 | |
| SCHEMBL4161031 | 0.80 | CNR1 (0.46) | AKR1B1AKR1A1ALDH1A1POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV5, TRPV2 | AKR1B1 344/4885AKR1A1 310/4885ALDH1A1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.